Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Martin Bergram, Patrik Nasr, Fredrik Iredahl, Stergios Kechagias, Karin Rådholm & Mattias Ekstedt. (2022) Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care. Scandinavian Journal of Gastroenterology 57:1, pages 60-69.
Read now
Read now
Sarra Smati, Clémence M Canivet, Jérôme Boursier & Bertrand Cariou. (2021) Anti-diabetic drugs and NASH: from current options to promising perspectives. Expert Opinion on Investigational Drugs 30:8, pages 813-825.
Read now
Read now
Articles from other publishers (17)
George Agyapong, Farzaneh Dashti & Bubu A. Banini. (2023) Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies. Annals of the New York Academy of Sciences 1526:1, pages 16-29.
Crossref
Crossref
Juan M. Pericàs, Nicholas A. Di Prospero, Quentin M. Anstee, Peter Mesenbrinck, Mette S. Kjær, Jesús Rivera‐Esteban, Franz Koenig, Elena Sena, Raluca Pais, Ramiro Manzano, Joan Genescà, Frank Tacke & Vlad Ratziu. (2023) Review article: The need for more efficient and patient‐oriented drug development pathways in NASH—setting the scene for platform trials. Alimentary Pharmacology & Therapeutics 57:9, pages 948-961.
Crossref
Crossref
Kok-Yong Chin, Sophia Ogechi Ekeuku, Deborah Chia Hsin Chew & Anne Trias. (2023) Tocotrienol in the Management of Nonalcoholic Fatty Liver Disease: A Systematic Review. Nutrients 15:4, pages 834.
Crossref
Crossref
Neeta B. Amin, Aditi R. Saxena, Veena Somayaji & Robert Dullea. (2023) Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology. Clinical Therapeutics 45:1, pages 55-70.
Crossref
Crossref
M.S. Poornima, G. Sindhu, Abraham Billu, C.R. Sruthi, P. Nisha, Pinku Gogoi, Gakul Baishya & K. G Raghu. (2022) Pretreatment of hydroethanolic extract of Dillenia indica L. attenuates oleic acid induced NAFLD in HepG2 cells via modulating SIRT-1/p-LKB-1/AMPK, HMGCR & PPAR-α signaling pathways. Journal of Ethnopharmacology 292, pages 115237.
Crossref
Crossref
Yoshio Sumida. (2022) Renaming from nonalcoholic fatty liver disease to metabolism dysfunction associated fatty liver disease: Pros and cons. Hepatology Research 52:5, pages 415-416.
Crossref
Crossref
Theodor Baars, Robert K. Gieseler, Polykarpos C. Patsalis & Ali Canbay. (2022) Towards harnessing the value of organokine crosstalk to predict the risk for cardiovascular disease in non-alcoholic fatty liver disease. Metabolism 130, pages 155179.
Crossref
Crossref
Bo Kyung Koo & Soo Lim. 2022. Clinical Obesity in Adults and Children. Clinical Obesity in Adults and Children
159
177
.
Zobair M. Younossi & Linda Henry. (2022) Fatty Liver Through the Ages: Nonalcoholic Steatohepatitis. Endocrine Practice 28:2, pages 204-213.
Crossref
Crossref
Scott L. Friedman & Massimo Pinzani. (2022) Hepatic fibrosis 2022: Unmet needs and a blueprint for the future. Hepatology 75:2, pages 473-488.
Crossref
Crossref
Martin Bossart, Michael Wagner, Ralf Elvert, Andreas Evers, Thomas Hübschle, Tim Kloeckener, Katrin Lorenz, Christine Moessinger, Olof Eriksson, Irina Velikyan, Stefan Pierrou, Lars Johansson, Gabriele Dietert, Yasmin Dietz-Baum, Thomas Kissner, Irene Nowotny, Christine Einig, Christelle Jan, Faiza Rharbaoui, Johann Gassenhuber, Hans-Peter Prochnow, Inoncent Agueusop, Niels Porksen, William B. Smith, Almut Nitsche & Anish Konkar. (2022) Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. Cell Metabolism 34:1, pages 59-74.e10.
Crossref
Crossref
Yoshio Sumida, Masato Yoneda, Yuya Seko, Hirokazu Takahashi, Nagisa Hara, Hideki Fujii, Yoshito Itoh, Masashi Yoneda, Atsushi Nakajima & Takeshi Okanoue. (2021) Role of vitamin E in the treatment of non-alcoholic steatohepatitis. Free Radical Biology and Medicine 177, pages 391-403.
Crossref
Crossref
Madamanchi Geethangili, Chiao-Wei Lin, Harry Mersmann & Shih-Torng Ding. (2021) Methyl Brevifolincarboxylate Attenuates Free Fatty Acid-Induced Lipid Metabolism and Inflammation in Hepatocytes through AMPK/NF-κB Signaling Pathway. International Journal of Molecular Sciences 22:18, pages 10062.
Crossref
Crossref
Hideki Fujii, Shinya Fukumoto, Masaru Enomoto, Sawako Uchida-Kobayashi, Tatsuo Kimura, Akihiro Tamori, Yuji Nadatani, Shingo Takashima, Naoki Nishimoto & Norifumi Kawada. (2021) The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases. Scientific Reports 11:1.
Crossref
Crossref
A. E. Bagriy, A. D. Zubov, M. V. Khomenko, E. S. Mikhailichenko, E. A. Pylaeva, N. A. Khaustova & E. V. Bryukhovetskaya. (2021) Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Russian Journal of Gastroenterology, Hepatology, Coloproctology 31:2, pages 14-26.
Crossref
Crossref
Niki Katsiki & Christos Mantzoros. (2021) Making progress towards a better pathophysiological understanding and more promising therapeutic options for treating non-alcoholic steatohepatitis (NASH)/DASH (dysmetabolism associated steatohepatitis). Metabolism 114, pages 154333.
Crossref
Crossref
Haiou Li, Yunjiao Zhou, Haizhou Wang, Meng Zhang, Peishan Qiu, Mengna Zhang, Ruike Zhang, Qiu Zhao & Jing Liu. (2020) Crosstalk Between Liver Macrophages and Surrounding Cells in Nonalcoholic Steatohepatitis. Frontiers in Immunology 11.
Crossref
Crossref